Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy
Journal of Hepato-Biliary-Pancreatic Sciences · 2026
DOI: 10.1002/jhbp.70058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, 2026. Verfasst von Tsuyoshi Takeda und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neoadjuvant Therapy, Deoxycytidine, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 25 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Neoadjuvant chemotherapy (NAC) with gemcitabine and S‐1 (GS) is the standard regimen for resectable pancreatic cancer (PC) in Japan. However, its efficacy in elderly patients and those with impaired renal function remains unclear.
Methods
We retrospectively analyzed patients with resectable PC who received NAC GS. Patients were classified as elderly (≥ 75 years) or non‐elderly (< 75 years). The primary endpoint was relative dose intensity (RDI) of NAC. Secondary endpoints included adverse events (AEs), perioperative outcomes, RDI of adjuvant chemotherapy (AC), recurrence‐free survival (RFS), and overall survival (OS).
Results
A total of 185 patients were included (non‐elderly: 148, elderly: 37). Median creatinine clearance (CCr) was lower in elderly patients (64.2 vs. 84.5 mL/min, p < 0.001). Mean RDI of GS was significantly lower in elderly patients and those with CCr < 50 mL/min, particularly when both factors coexisted. Severe hematologic AEs were more frequent in these groups, though perioperative outcomes were similar. While initiation of AC was delayed and RDI of adjuvant S‐1 was lower in elderly patients, RFS and OS did not significantly differ between groups.
Conclusions
NAC GS appears feasible in elderly patients with resectable PC, though caution is needed in those with impaired renal function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
- Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
ORCID-Profile: Takashi Sasaki, Yosuke Inoue, Takafumi Mie, Takaaki Furukawa, Takeshi Okamoto
Zitieren
APA
Takeda, T., Ozaka, M., Sasaki, T., Inoue, Y., Hirai, T., Mie, T., Furukawa, T., Okamoto, T., Takahashi, Y., & Sasahira, N. (2026). Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy. Journal of Hepato-Biliary-Pancreatic Sciences. https://doi.org/10.1002/jhbp.70058
Vancouver
Takeda T, Ozaka M, Sasaki T, Inoue Y, Hirai T, Mie T, et al. Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy. Journal of Hepato-Biliary-Pancreatic Sciences. 2026. doi:10.1002/jhbp.70058
BibTeX
@article{Takeda2026,
author = {Takeda, Tsuyoshi and Ozaka, Masato and Sasaki, Takashi and Inoue, Yosuke and Hirai, Tatsuki and Mie, Takafumi and Furukawa, Takaaki and Okamoto, Takeshi and Takahashi, Yu and Sasahira, Naoki},
title = {Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy},
journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
year = {2026},
doi = {10.1002/jhbp.70058}
}
EUVIMED